Trail activity in human ovarian cancer cells: potentiation of the action of cytotoxic drugs - PubMed (original) (raw)
Trail activity in human ovarian cancer cells: potentiation of the action of cytotoxic drugs
S Vignati et al. Eur J Cancer. 2002 Jan.
Abstract
The ability of the TRAIL ligand to induce cell killing in three ovarian cancer cell lines was investigated using a glutathione-S-transferase (GST)-TRAIL fusion protein. One of the three lines was sensitive to TRAIL, which induced cell killing in a range of concentrations similar to those necessary to kill the TRAIL-sensitive leukaemic cell line Jurkat. The relative mRNA expression of the four TRAIL receptors did not explain the different sensitivities of the three ovarian cancer cell lines to TRAIL treatment. The TRAIL-sensitive IGROV-1 cell line expressed slightly lower levels of the anti-apoptotic protein FLIP than the two TRAIL-insensitive cell lines (A2780 and SKOV-3). Nevertheless, although TRAIL did not significantly reduce cell growth in the A2780 and SKOV-3 cells it did enhance the activity of paclitaxel and cisplatin (DDP), the two most widely used drugs for the treatment of ovarian cancer, increasing their ability to induce apoptosis. The use of TRAIL in combination with classical anticancer agents might thus boost the apoptotic response, improving the activity of DDP and paclitaxel in ovarian cancer.
Similar articles
- Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs.
Tomek S, Horak P, Pribill I, Haller G, Rössler M, Zielinski CC, Pils D, Krainer M. Tomek S, et al. Gynecol Oncol. 2004 Jul;94(1):107-14. doi: 10.1016/j.ygyno.2004.04.012. Gynecol Oncol. 2004. PMID: 15262127 - Synergistic antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand combined with cisplatin in ovarian carcinoma cell lines in vitro and in vivo.
Liu P, Mao H, Hou P. Liu P, et al. Int J Gynecol Cancer. 2006 Mar-Apr;16(2):538-48. doi: 10.1111/j.1525-1438.2006.00507.x. Int J Gynecol Cancer. 2006. PMID: 16681723 - Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
Cuello M, Ettenberg SA, Nau MM, Lipkowitz S. Cuello M, et al. Gynecol Oncol. 2001 Jun;81(3):380-90. doi: 10.1006/gyno.2001.6194. Gynecol Oncol. 2001. PMID: 11371126 - Potential and caveats of TRAIL in cancer therapy.
Held J, Schulze-Osthoff K. Held J, et al. Drug Resist Updat. 2001 Aug;4(4):243-52. doi: 10.1054/drup.2001.0208. Drug Resist Updat. 2001. PMID: 11991679 Review. - Potential for TRAIL as a therapeutic agent in ovarian cancer.
Abdollahi T. Abdollahi T. Vitam Horm. 2004;67:347-64. doi: 10.1016/S0083-6729(04)67018-X. Vitam Horm. 2004. PMID: 15110185 Review.
Cited by
- 2-methoxyestradiol mediates apoptosis through caspase-dependent and independent mechanisms in ovarian cancer cells but not in normal counterparts.
Kato S, Sadarangani A, Lange S, Delpiano AM, Vargas M, Brañes J, Carvajal J, Lipkowitz S, Owen GI, Cuello MA. Kato S, et al. Reprod Sci. 2008 Nov;15(9):878-94. doi: 10.1177/1933719108324171. Reprod Sci. 2008. PMID: 19050321 Free PMC article. - Inhibition of CRM1 activity sensitizes endometrial and ovarian cell lines to TRAIL-induced cell death.
Fabi F, Adam P, Vincent K, Demontigny F, Parent S, Joncas FH, Asselin E. Fabi F, et al. Cell Commun Signal. 2018 Jul 4;16(1):39. doi: 10.1186/s12964-018-0252-z. Cell Commun Signal. 2018. PMID: 29973205 Free PMC article. - Tumor necrosis factor-related apoptosis ligand induces apoptosis in prostate cancer PC-3M cell line.
Chen Z, Wang H, Gu L, Ye Z, Xiao Y. Chen Z, et al. J Huazhong Univ Sci Technolog Med Sci. 2005;25(4):442-4, 447. doi: 10.1007/BF02828218. J Huazhong Univ Sci Technolog Med Sci. 2005. PMID: 16196298 - OSMI-1 Enhances TRAIL-Induced Apoptosis through ER Stress and NF-κB Signaling in Colon Cancer Cells.
Lee SJ, Lee DE, Choi SY, Kwon OS. Lee SJ, et al. Int J Mol Sci. 2021 Oct 14;22(20):11073. doi: 10.3390/ijms222011073. Int J Mol Sci. 2021. PMID: 34681736 Free PMC article. - Upregulation of microRNA135a-3p and death receptor 5 plays a critical role in Tanshinone I sensitized prostate cancer cells to TRAIL induced apoptosis.
Shin EA, Sohn EJ, Won G, Choi JU, Jeong M, Kim B, Kim MJ, Kim SH. Shin EA, et al. Oncotarget. 2014 Jul 30;5(14):5624-36. doi: 10.18632/oncotarget.2152. Oncotarget. 2014. PMID: 25015549 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials